SCHEMBL10241916

SCHEMBL10241916

NC(=O)c1cnc(Nc2ccc(S(N)(=O)=O)cc2)nc1Nc1ccc2ncsc2c1

nearest known ligand 0.66

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SYK P43405 15/20 0.66
PDE4B Q07343 1/20 0.54
MAPK8 P45983 1/20 0.49
MAPK9 P45984 1/20 0.49
CYP3A4 P08684 1/20 0.48
IRAK4 Q9NWZ3 1/20 0.48
CDK1 P06493 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16782386 0.81 SYK (0.69) SYKMAPK8IRAK4
SCHEMBL764195 0.81 SYK (0.64) SYKMAPK8MAPK9
SCHEMBL10242655 0.81 SYK (0.64) SYK
SCHEMBL10242640 0.80 SYK (0.85) SYK
SCHEMBL10244483 0.80 SYK (0.71) SYKMAPK8MAPK9CDK1
SCHEMBL764198 0.80 SYK (0.69) SYKMAPK8MAPK9
SCHEMBL10241920 0.80 SYK (0.58) SYKMAPK8MAPK9CDK1
SCHEMBL1354374 0.80 SYK (1.00) SYK
SCHEMBL1354368 0.80 SYK (1.00) SYK
SCHEMBL763194 0.79 SYK (0.62) SYKMAPK8MAPK9IRAK4CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138339-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-03-20 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 SYK 1/4885PDE4B 3654/4885MAPK8 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.